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hascomefromsmallanimalmodels,signiﬁcantdiﬀerences existwithregard tocardiovascularcharacteristics between thesemodels
and humans. Therefore, large animal models are essential to develop the discoveries from murine models into clinical therapies
andinterventions.This paper will provide an overview of the more frequently used large animalmodels, especially porcine models
for preclinical studies.
1.Introduction
Therapies for the treatment of cardiovascular disease have
advanced dramatically over the last 2 decades. To improve
human health, scientiﬁc discoveries and technologies must
be translated into practical applications. Such advances
typically begin with basic research and then progress to
the clinical level. Inherent in the development of these
technologies is the role of preclinical testing using animal
models. Although no animal model can fully replicate
the complexity of human pathological conditions, animal
models are key for the evaluation of mechanisms of disease
and testing of diagnostic technologies and interventions.
Signiﬁcant insight into the molecular and cellular basis
of cardiovascular biology has come from small animal
models, particularly mice. However, signiﬁcant diﬀerences
existwith regard tocardiovascular characteristics, whenmice
are compared to humans. Therefore, large animal models
that approximate human physiology, function, and anatomy,
are essential to develop discoveries from murine models into
clinical therapies and interventions.
This paper will provide an overview of the more fre-




Recent years have seen 2 important changes to the clinical
approach involving acutemyocardial infarction (AMI).First,
there is increasing recognition that the pathophysiology
of human AMI is a process occurring at many levels,
not just within the epicardial coronary artery, but also
within the microvasculature and the myocardium. Second,
contemporary treatments are shifting from thrombolytic
dissolution of epicardial coronary thrombus to direct
mechanical approaches such as angioplasty and stents. On
the other hand, chronic reversible contractile dysfunction
(hibernation) is frequently identiﬁed in the evaluation
of patients with coronary artery disease and constitutes
an intense area of clinical interest. Thus, the following
discussion reviews and examines current animal models
of AMI/chronic hibernation and discusses advantages and
limitations, providing an overview of their place in these
important models of AMI.
2.1. Animal Myocardial Infarction/Reperfusion Model. Tra-









Figure 1: Porcine (a and b). (a) Right coronary artery. (b) Left coronary system. Human (c and d). (c) Right coronary artery. (d) Left
coronary system. Similar anatomy and coronary distribution is shown of the left anterior descending, left circumﬂex, and right coronary
arteries.
as the most frequently used animal species yet due to
cost and social pressures, the porcine model has become a
more favored animal only in recent years [1, 2]. To induce
myocardial ischemia, whereas the left descending coronary
artery (LAD) is most frequently used to produce regional
myocardial ischemia, left circumﬂex coronary artery (LCx)
occlusions have also been used. A number of studies have
been performed in open-chest models with thoracotomy [3,
4]. This approach allows easy access to the heart with direct
visual control of the success of coronary artery occlusionand
the opportunity to measure local contractile performance,
metabolic parameters, and coronary ﬂow using ultrasound
techniques [5–7]. However, disadvantages of this open-chest
model stem from having to open the chest and pericardium,
both of which are suspected and reported to inﬂuence the
pattern of left ventricular remodeling in chronic models
[8, 9]. To eradicate these disadvantages, several groups
havereportedcatheter-based closed-chesttechniques[9–12].
Cardiac catheterization and coronary intervention in the pig
and in humans are similar in many ways (Figure 1). Through
the use of an intracoronary balloon inﬂation technique, both
the location and duration of coronary artery occlusion are
well controlled. In our laboratory, once baseline coronary
angiography is performed, the middle portion of LAD distal
to the 1st diagonal branch is primarily chosen as the targeted
occlusionlocationto induce MI [12]( Figure 2).In ourexpe-
rience, 60-minute mid-LAD occlusion is the most feasible
location and timeframe to develop a porcine reperfused
myocardial infarction model [12]. A commonly perceived
diﬃculty of using the pig MI model is a predisposition
for refractory arrhythmogenesis. Thus, it is known from
previous reports using the porcine myocardial model, that
there is a high incidence of ventricular ﬁbrillation (VF) or
ventricular tachycardia (VT) after induction of myocardial
infarction coupled with greater mortality due to infarct-
related complications. All VF episodes occurred within the
ﬁrst 20–30 minutes after induction of myocardial infarction
and within the ﬁrst 10 minutes after reperfusion [12].
However, methods have been described to obviate this issue,
such as aggressive airway protection and ventilatory man-
agement, electrolyte supplementation, and antiarrhythmic
administration.
For histological assessment of injured myocardium,
2,3,5-Triphenyltetrazolium chloride (TTC) was commonly
used. In viable myocardium, TTC is converted by dehydro-
genases to a red formazan pigment that stains the tissue dark
red. In necrotic myocardium, however, such staining does
not occurbecause of the loss of dehydrogenases. To delineate
areas at risk for ischemia and infarcted (necrotic) areas more
clearly, our group performs in vivo a double staining methodJournal of Biomedicine and Biotechnology 3
with 1% Evans blue dye and a 1% solution of TTC [12]
(Figure 3).
2.2. Animal Models with Hibernating Myocardium. Myocar-
dial hibernation, as originally described by Rahimtoola [13],
was thought to represent “a state of persistently impaired
myocardial and left ventricular function at rest because
of reduced coronary blood ﬂow that can be partially or
completely restored to normal if the myocardial oxygen
supply/demand relationship is favorably altered, either by
improving blood ﬂow or by reducing demand.” Chronic
reversible contractile dysfunction is frequently identiﬁed in
theevaluationofpatientswith coronaryartery disease. There
has been considerable interest in prospectively identifying
patients with chronic left ventricular contractile dysfunction
that improves following coronary revascularization. PET
and other noninvasive quantitative imaging modalities have
advanced our understanding of the mechanisms involved
with hibernating myocardium in patients [14–17]. From
these advances, several studies were initiated to investigate
suitableanimal models. Usually, larger animals such as swine
or dogs are used for developing a hibernating myocardium
model.Initially,Matsuzakietal.attemptedtodevelopanimal
hibernation models through steady-state acute ischemia and
short-term reduction in coronary ﬂow reserve [18]. As a
result, these models have provided insight into the initial
adaptive response of the heart to acute ischemia, indicating
that it can be maintained for several hours without the
development of signiﬁcant necrosis. Other groups have
attempted to extend the duration of ischemia to 24 hours
and 1 week for developing viable chronically dysfunctional
myocardium [19–21]. Although these attempts resulted in
regional dysfunction and a stenosis-induced reduction in
coronary ﬂow, one major drawback noted was that this
approach resulted in irreversible injury that producedpatchy
necrosis visible by TTC in some animals and focal necrosis
by light microscopy in most animals. These early animal
experiments of short-term reductions in myocardial ﬂow
seemed to support this “smart” heart concept [22]i n
which myocardial function is downregulated to the point at
which perfusion and function are once again in equilibrium.
Chronic stenosis models that reduce coronary ﬂow reserve
appear to be more applicable to understanding factors gov-
erningthedevelopmentofviabledysfunctional myocardium.
Canty and Klocke have demonstrated that viable chronically
dysfunctional myocardium could be reproduced in dogs
[23], and Shen and Vatner have subsequently reproduced a
similar stateof chronic stunning using an Ameroid occcluder
intheporcinemodel[24].FallavollitaandCantyhavefurther
demonstrated that resting dysfunction worsened from 1
month to 2 months after operation despite resting perfusion
at both time points being normal, consistent with a state of
chronic stunning and hibernating myocardium with reduced
resting coronary ﬂow and increased FDG uptake developed
at3-4monthsafteroperation[25].Althoughthemostwidely
used animal model of hibernating myocardium has been
the Ameroid stenosis, the disadvantage of this approach is
that both the rate and extent of progression of the Ameroid
stenosis and the rate of collaterals are unpredictable. In
addition, there is a large variation in the reported percent
infarction of the area-at-risk (5 to 100%). As a model of
human coronary artery disease, thismodel has itslimitations
[19–21, 23–30].
3.ExperimentalPorcine CoronaryModel
The coronary artery system of domestic pigs is in similar
fashion to human coronary arteries [31, 32]. Furthermore,
when porcine coronary arteries are injured, thick neointima
is seen within 28 days and is identical to human restenotic
neointima (Figure 4). In addition, the amount of neoin-
timal thickening is directly proportional to injury thereby
permitting the creation of an injury-response regression
relationship that can further quantify the response to poten-
tial treatment therapies [33, 34]. Cardiac catheterization
techniques in the pig are similar to the techniques used
in humans. Standard human diagnostic and interventional
equipment can also be used. Thus, coronary arteries in
domestic swine are suitable for the assessment of catheter-
based interventional devices that may be used in humans.
3.1.The EvaluationofStentTechnologies. Drug-elutingstents
(DES) have driven a new era into the ﬁeld of percuta-
neous coronary intervention [35, 36]. The success of this
technology is founded not only on initial human clinical
data but also on preclinical studies using the porcine
coronary restenosis model [37–40]. Presently, it is unclear
whether any single animal species is more predictive of the
human response than another. These animal models can
therefore help prove critical hypotheses regarding putative
mechanisms of action of an intervention yet cannot be
used to predict eﬃcacy [41, 42]. Regarding DES evaluation,
recommendationsfromapreclinicalstudiesconsensusgroup
suggest that the stent should be appropriately sized by
visual or quantitative coronary artery measurement using a
stent:artery ratio ≤1:1, while using a higher stent:artery
ratio could induce severe arterial injury and considerable
coronary artery stenosis [41, 42]. For the evaluation of stent
performance, a rigorous, (semi)quantitative and deﬁned
scale for device evaluation should be presented such as
injury/inﬂammation score, vascular response/healing, and
stent strut apposition/adjacent tissue as previously reported
[43–48].
Although preclinical studies of both sirolimus-eluting
stents (SESs) and paclitaxel-eluting stents (PESs) have
demonstrated eﬃcacy compared with bare metal stents
(BMSs), enthusiasm for this technology has recently been
dampened by concerns of late stent thrombosis. Nakazawa
et al. has reported that incomplete endothelial coverage was
seen in nonoverlapping and overlapping sites of both SES
and PES compared with both the Endeavor zotarolimus-
eluting stent (ZES; Medtronic Vascular, Santa Rosa, CA)
and BMS and that the diﬀerences were more pronounced
in the overlapping segments [49]( Figure 5). In addition,
two studies using human autopsy samples suggested that
incomplete endothelial coverage of stent struts played an4 Journal of Biomedicine and Biotechnology
(a) (b)
Figure 2: Baseline coronary angiogram was obtained for assessment of anatomic information of the LAD (a). The LAD with the ﬁrst large
diagonal artery (white arrowhead) is delineated. Angiographic conﬁrmation of complete occlusion in the midportions (b) of the LAD with









Figure 3: This picture demonstrates the porcine heart (a) and cross-sectional slice (b). The dark area stained with Evans Blue indicates
nonischemic territory, and the red area stained with TTC is the area at risk for ischemia (TTC-positive). In (b), the white area is the
infarcted (necrotic) myocardium(TTC-negative). The schemaexplains what the stained colorsand territories indicate (c). LAD: left anterior
descending artery. Adapted from [12].
important role as the morphometric predictor of late stent
thrombosis [52, 53]. From these reports, two time points are
implicatedforuse intheevaluationofstentperformance: the
ﬁrst at 28 days to observe for neointimal hyperplasia, and at
least one later time point to examine long-term eﬀects. The
lattertime point (3or6 months) dependson when “healing”
and drug release are both complete. Of note, the FDA has
typically recommended 6-month follow-up as the interval to
acquirepreclinicalstentdata[41,42],yetthiswindowreﬂects
experience with balloon angioplasty and not necessarily the
“window” for drug-eluting stents.
3.2. Porcine Heat-Injury Restenosis Model. The porcine coro-
nary stent restenosis model is a well-accepted standard;
























Figure 4: (a) Photomicrographic section shows gross neointimal proliferation causing a signiﬁcant stenosis (Hematoxylin-Eosin stain, x5).
(b) In thissection,the porcine coronarywastotallyoccluded withneointimalhyperplasia.L:lumen;M:media;NI:neointima;∗:s t e n ts t r u t .
Adapted from the reference [32].







Figure 5: (a) X-rays of longitudinally cut rabbit iliac arteries at 21 days after placement of overlapping ZES, SES, and PES. The extent of
stentcoverageby endothelialcells wasgreatestwithZES,withalmostcompletecoverageintheproximalanddistalsegmentsandsigniﬁcantly
greatercoverage intheoverlapped segmentcomparedwithSESandPES.(b)Photomicrographsshowingthe amountofneointimalthickness
at 28 days after placement of Endeavor zotarolimus-eluting stents (ZESs), Cypher sirolimus-eluting stents (SESs), Taxus paclitaxel-eluting
stents (PESs), and Driver bare metal stents (BMSs) in rabbit iliac arteries. With SES, there were focally uncovered stent struts, which were
associated with inﬂammation consistingof heterophils or eosinophils and giant cells. Adapted from [49].6 Journal of Biomedicine and Biotechnology
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Figure 6: Time course of coronary artery treated with thermal balloon. A severe tandem coronary artery stenosis is observed in the left
anterior descending artery (LAD) at 4 weeks after thermal balloon injury [50].
foreign material. As a result, this model may not be suitable
to evaluate the performance of bifurcation or bioabsorbable
stents due to lack of a true stenosis lesion. Also, results
of coronary artery imaging such as computed tomography
(CT), magnetic resonance imaging (MRI), intravascular
ultrasound (IVUS), and optical coherence tomography
(OCT) may be hampered as the stent can produce artifact.
Using radiofrequency thermal balloon angioplasty, Staab
et al. [54] and our laboratory [50]h a v ei n v e s t i g a t e da
porcine heat-injury restenosis model. In our study using
22 swine with a total of 54 coronary arteries, coronary
artery stenoses were consistently developed at 4 weeks
after heat-injury (Figure 6). In light of these results, this
porcine coronary restenosis model might be useful for the
evaluation of bifurcation stents and bioabsorbable stents,
coronary imaging studies as listed above, and as part of
the technical training for complex percutaneous coronary
interventions such as bifurcation, diﬀuse lesion, and chronic
total occlusion [50].
3.3. Porcine Chronic Total Occlusion (CTO) Model. Recent
advances of DES technology have shifted focus within
interventional cardiology from restenosis prevention to the
treatment of CTO. Despite its common occurrence, there
is surprisingly little information about the pathophysiology
of CTO, and why some CTO can be crossed while in
others, crossing is unsuccessful. For the past several years,
researchers havedevelopedCTOmodelstoguidetherapeutic
investigations.
Spontaneous atherosclerotic plaque rupture and subse-
quentarterial occlusiondo not occur naturally in any animal
model, even among models genetically engineered to have
increased atheroma formation. The initial method of pro-
ducing a total occlusionutilized external ligature orAmeroid
constriction [55]. However, one fundamental drawback of
this method is the inability to facilitate the development of
devices to recanalize CTO. Strauss et al. subsequently mod-
iﬁed the thrombin injection model by infusing collagenase
[56]. Several characteristics of human CTO were evident in
this model, including mature ﬁbrous tissue, multiple small
intraluminal vascular channels, occasional extracellular lipid
deposits, and disruption of the internal elastic lamina. Their
reports suggested that the microchannels might be a critical
determinant of successful CTO guide wire crossing [57].
Other CTO models have included stents with occluded out-
ﬂow and have even used direct alcohol injection to promote
thrombosis [58]. Developing an accurate and reproducible
human-like coronary CTO model has been a complex
undertakingbecause(1)coronaryvesselsarelessamenableto
adirectsurgicalapproach;(2)simulatingluminalandmedial
pathology, including microcalciﬁcation, has been diﬃcult;
(3) an inﬂammatory component must be present to mimic
human CTO lesions [59, 60]. Balloon angioplasty and stent
implantation in animal coronary arteries, both standard
methods of denuding the vessel and engendering neointimal
proliferation, rarely result in CTO development. Polymers
have also been used to invoke chronic coronary occlusions.
Early polymeric implants were abandoned as stent platforms




Figure 7: Histological examinations of pig experiments. Elastic-van Gieson (a, b) and Von kossa (c, d) stained CTO segment of coronary
arteries. Arrows in (c) and (d) indicate microcalciﬁcation. Ex vivo micro-CT conﬁrms that CTO lesions contain calciﬁcation in LAD (red
circle) [51].
vessel occlusion [61]. Prosser et al. reported placement of
a microporous poly L-lactic acid polymer into pig and
dog coronary arteries [62]. The polymer is absorbed by 28
days, resulting in a microchanneled occlusion histologically
similar toahumanCTO.Usingsimilar methods,Suzukietal.
[63] and our laboratory [51] have developed severe calciﬁed
CTO in pig coronary arteries (Figure 7). These animal
models may contribute to a more in-depth understanding
of the biology of human CTO and enable new device and
pharmacological investigations to improve recanalization
success in these challenging lesions.
3.4. Animal Model of Vulnerable Plaque. The deﬁnition of a
“vulnerable” plaque is now accepted that most clinical man-
ifestations of atherosclerosis such as AMI, unstable angina,
and sudden cardiac death result from the development
of an occlusive thrombus over an underlying plaque. The
mechanisms of plaque rupture and subsequence occlusive
thrombus formation are still unclear. Thus, animal models
of high-risk (vulnerable) plaque are pivotal in the develop-
ment and validation to identify and characterize vulnerable
atherosclerotic lesions in humans. Recent models of plaque
vulnerability continue to use small animals, particularly8 Journal of Biomedicine and Biotechnology
mice;howevermostdonotresultinfeaturesrepresentativeof
human end-stage atherosclerosis. Characteristics of human
vulnerable plaque such as plaque disruption, neovascular-
ization, intraplaque hemorrhage, and occlusive thrombus
formation occur rather infrequently in murine models. In
addition, lipoprotein metabolism in mice is largely diﬀerent
from that in humans, thus a murine model may not be
suitable for studies examining the eﬀects of hypolipidemic
therapies on atherosclerosis or myocardial infarction. In
studies using large animals, Granada et al. reported that
percutaneous intramural injection of cholesteryl linoleate
results in the development of complex, lipid-containing
i n ﬂ a m m a t o r yl e s i o n si nl e s st h a n4w e e k sa n dt h a tt h e
intravascular ultrasound ﬁndings for the lesions created
in this model demonstrate similar features to those of
complex human atherosclerotic plaques [64, 65]. However,
this model is rich in smooth muscle cells/proteoglycans, and
the lesions lack a necrotic core, calciﬁcation, and collagen
(type I). Hasler-Rapacz et al. described a strain of large
domestic swine which develop elevated LDL levels and
subsequently develop human-like atherosclerotic lesions by
12 months of age [66, 67]. Gerrity et al. also demonstrated
the combination of induced diabetes by intravenous infu-
sion of streptozotocin as well as hypercholesterolaemia by
administration of a high cholesterol diet in Yorksire pigs,
leading to advanced atherosclerotic lesions [68]. Although
these porcine models develop human-like atherosclerosis,
a major limitation is the time duration necessary for the
development of advanced coronary lesions.
Shiomi et al. have developed the MI model, designated
the Watanabe heritable hyperlipidemic (WHHL) rabbit, in
which sudden cardiac events occur spontaneously without
any artiﬁcial treatment [69]. In their study, the cumulative
incidence of fatal sudden cardiac events up to the age of 35
months was 97%, and representative ﬁndings of myocardial
infarction (MI) such as vulnerable plaques as deﬁned by
Naghavi et al. [70] and thrombosis were observed in the
hearts of those rabbits. This WHHL MI rabbit could be a
very useful model for studying the mechanism(s) of plaque
rupture and thrombogenesis and provide a novel means for
developing new therapies or imaging technologies.
Currently, there is no standard animal model for vulner-
able plaque. The availability of animal models of human-
like atherosclerosis will become the most critical element for
the preclinical validation of emerging diagnostic/therapeutic
technologies developedfor use in patients with symptomatic
coronary artery disease.
4.Conclusions
Clinical implementation of innovative diagnostic and thera-
peutic technologies will ultimately depend on the successful
development of large animal models that permit preclinical
evaluation of the technology. The ﬁeld of percutaneous
cardiovascular intervention technology is developingquickly
and reﬂects the time sensitivity of the information con-
tained within this paper. The success of this interventional
subspecialty will be driven by the results of a collaborative
relationship between the cardiologist, cardiac surgeon, and
the medical device industry.
In addition, the role of animal models should be not
only in device developmentand durability testing but also in
training for clinicians in optimal techniques involving new
procedures.
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